Peptide · Fact sheet
Tirzepatide
Also known as Mounjaro · Zepbound
Tirzepatide is FDA approved in specific prescription products and populations. Zepbound also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
What is Tirzepatide?
Tirzepatide is a manufactured medicine that activates two receptors involved in metabolic signaling: GIP and GLP-1.
Mounjaro and Zepbound contain the same active ingredient but have distinct FDA-labeled uses.
Benefits & claims
Interest centers on blood-sugar control, body-weight outcomes, and the obstructive-sleep-apnea indication.
It is also being studied for cardiovascular, kidney, and liver outcomes.
What the evidence supports
- Trials supporting approved labels found benefits in their specified metabolic and sleep-apnea outcomes.
- Additional outcome studies may clarify where benefits extend beyond current labels.
Research areas
- Type 2 diabetes
- Chronic weight management
- Obstructive sleep apnea in adults with obesity
- Cardiovascular and kidney outcomes
- Metabolic liver disease
- Additional cardiovascular, kidney, and liver outcomes
- Other uses not listed in a current product label
Dosage & frequency
Product-specific label informationMounjaro and Zepbound use weekly tirzepatide but have different indications, populations, and maintenance amounts.
Mounjaro
Adults and patients age ten years and older with type 2 diabetes
- Amount
- Start 2.5 mg for four weeks, then 5 mg; eligible 2.5 mg increases at least four weeks apart
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
Maximum 15 mg in adults; 10 mg in pediatric patients.
Zepbound: weight management
Adults meeting labeled weight-management criteria
- Amount
- Start 2.5 mg; maintenance 5, 10 or 15 mg after label escalation
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
2.5 mg is not maintenance; escalation steps require at least four weeks.
Zepbound: obstructive sleep apnea
Adults with obesity and moderate-to-severe obstructive sleep apnea
- Amount
- 10 or 15 mg maintenance after label escalation
- Frequency
- Once weekly
- Route studied or labeled
- Subcutaneous
Indication-specific maintenance amounts.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Mounjaro is the diabetes product; Zepbound covers adult weight management and obstructive sleep apnea in adults with obesity.
Interactions & precautions
- Insulin or insulin secretagogues increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
- The labels warn that oral hormonal contraceptive effectiveness may be reduced after starting treatment or increasing the dose.
What is still unresolved
- Different indications can require different maintenance choices.
Side effects & risks
- Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and other gastrointestinal symptoms.
- Current labeling includes a boxed warning about thyroid C-cell tumors in rats and important contraindications.
- Other labeled concerns include pancreatitis, gallbladder problems, kidney injury, hypoglycemia with certain medicines, and aspiration risk around anesthesia or deep sedation.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesLarge randomized trials support approved indications. Results cannot be assumed to apply to unstudied populations, products, or claims.
Studies
Registry record for a pivotal tirzepatide chronic-weight-management trial.
Peer-reviewed report of tirzepatide in adults with obesity.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| SURMOUNT-1 Adults with obesity or overweight plus a complication; diabetes excluded 2,539 participants (actual) Randomized placebo-controlled trial; human | Tirzepatide versus Placebo 72 weeks Primary: Percentage weight change and proportion reaching at least 5% reduction Phase: Phase 3 | Active groups had greater mean weight reduction than placebo. Cannot tell us: Weight change alone does not quantify cardiovascular-event or survival benefit; different active regimens are not pooled here. Safety, uncertainty, and source detailsGastrointestinal events were most common; adverse events led to discontinuation in both active and placebo groups. Limited to the studied population, formulation and follow-up. Funding/conflicts: Supported by Eli Lilly; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
| TRIUMPH-5 Adults with obesity 800 participants (estimated) Randomized placebo-controlled trial; human | Retatrutide versus Tirzepatide Primary weight endpoint: 80 weeks Primary: Percentage body-weight change Phase: Phase 3 | Active, not recruiting; no registry results posted at the source check. Cannot tell us: A registered head-to-head design is not a completed head-to-head result. Enrollment is estimated. Safety, uncertainty, and source detailsSee primary paper; absence of a signal in this study does not establish general safety. Limited to the studied population, formulation and follow-up. Funding/conflicts: Sponsor: Eli Lilly and Company. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
What did SURMOUNT-1 measure?
A placebo-controlled trial supports weight reduction in the studied adults. The OSA indication has its own label scope.
Limit: This weight trial alone does not establish cardiovascular-event prevention or prove every sleep-apnea indication.
Check the sources: SURMOUNT-1: tirzepatide and obesity (checked 2026-09-18) · FDA Zepbound prescribing information (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Zepbound: Weight management
Subcutaneous injection · Adults with obesity or overweight plus a weight-related condition
approved — Adjunct to reduced-calorie diet and increased physical activity.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Zepbound: Obstructive sleep apnea
Subcutaneous injection · Adults with obesity and moderate-to-severe obstructive sleep apnea
approved — Does not cover every cause or severity of sleep apnea.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Compare research questions · Submit a source-based correction
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Appetite: reported experiences
Little benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountLess preoccupation with food
A person describing two weeks with tirzepatide reported less constant thinking about meals and more mental space for work.
Reported use in this account
- Product
- Product labeled tirzepatide
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two weeks
This short, enthusiastic account is not a validated measure of cognition or a prediction of longer-term results. Selected public self-report; identity, product contents, other exposures and outcomes were not independently verified. It cannot establish causation or frequency.
Read the personal accountWeight: reported experiences
Long-term weight loss despite tolerability problems
A Mounjaro reviewer described substantial weight loss and feeling better after two years, alongside nausea, constipation, fatigue and food aversion.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two years
Other exposures described: Insulin and other medicines were reportedly stopped
This selected May 2024 review reports several medication changes without verified records. It cannot establish the cause of every change or predict another person’s results.
Read the original accountLittle benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountEnergy: reported experiences
Long-term weight loss despite tolerability problems
A Mounjaro reviewer described substantial weight loss and feeling better after two years, alongside nausea, constipation, fatigue and food aversion.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two years
Other exposures described: Insulin and other medicines were reportedly stopped
This selected May 2024 review reports several medication changes without verified records. It cannot establish the cause of every change or predict another person’s results.
Read the original accountHeadache, nausea and heartburn disrupted the first week
Another Mounjaro reviewer described several days of headache, nausea, fatigue and heartburn, despite early weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- First week described
This selected September 2022 review is unverified. It does not establish symptom frequency or a predictable adjustment period.
Read the original accountLittle benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountSleep: reported experiences
Little benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountFocus: reported experiences
Little benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountDigestion: reported experiences
Long-term weight loss despite tolerability problems
A Mounjaro reviewer described substantial weight loss and feeling better after two years, alongside nausea, constipation, fatigue and food aversion.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two years
Other exposures described: Insulin and other medicines were reportedly stopped
This selected May 2024 review reports several medication changes without verified records. It cannot establish the cause of every change or predict another person’s results.
Read the original accountHeadache, nausea and heartburn disrupted the first week
Another Mounjaro reviewer described several days of headache, nausea, fatigue and heartburn, despite early weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- First week described
This selected September 2022 review is unverified. It does not establish symptom frequency or a predictable adjustment period.
Read the original accountGlucose: reported experiences
Little benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountHeadache: reported experiences
Headache, nausea and heartburn disrupted the first week
Another Mounjaro reviewer described several days of headache, nausea, fatigue and heartburn, despite early weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- First week described
This selected September 2022 review is unverified. It does not establish symptom frequency or a predictable adjustment period.
Read the original accountLittle benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountNo clear change: reported experiences
Little benefit with fatigue and brain fog
A reviewer described repeated fatigue, headache, brain fog and sleep difficulty over several weeks, with little glucose change, continued hunger and no weight loss.
Reported use in this account
- Product
- Mounjaro
- Amount
- Not specified clearly
- Frequency
- Weekly
- Route
- Injection; specific route not stated
- Duration
- Several weeks
This selected June 2023 review lacks clinical records and full treatment context. It cannot identify the cause of symptoms or establish nonresponse criteria.
Read the original accountApproval status
Tirzepatide products are FDA approved for specific uses, including type 2 diabetes, chronic weight management, and—under the Zepbound label—moderate-to-severe obstructive sleep apnea in adults with obesity.
Approved uses
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults
- Moderate-to-severe obstructive sleep apnea in adults with obesity under the Zepbound label
FDA approved for product-specific uses
Mounjaro and Zepbound have FDA-approved indications, including diabetes, chronic weight management, and the Zepbound obstructive-sleep-apnea indication. The approval does not extend to every metabolic claim.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Outcomes for uses and populations not yet studied in large trials
- Very long-term outcomes across increasingly broad populations
- Whether every ongoing outcome trial will confirm early signals
- Quality and safety of products marketed outside approved supply chains
Summary
Tirzepatide has strong evidence for specific approved uses, but brand, indication, eligibility, contraindications, and clinical oversight all matter.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Mounjaro
Official tirzepatide prescribing information for a type 2 diabetes product.
- fdaFDA prescribing information: Zepbound
Official tirzepatide prescribing information for chronic weight management and obstructive-sleep-apnea indications.
- fdaFDA: first medication approved for obstructive sleep apnea
FDA announcement of the Zepbound obstructive-sleep-apnea indication.
- clinical trialsClinicalTrials.gov: SURMOUNT-1 tirzepatide trial
Registry record for a pivotal tirzepatide chronic-weight-management trial.
- pubmedSURMOUNT-1 tirzepatide randomized trial
Peer-reviewed report of tirzepatide in adults with obesity.